• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Boston Scientific wins FDA approval for imaged-guided software for DBS therapy

Boston Scientific wins FDA approval for imaged-guided software for DBS therapy

April 12, 2022 By Danielle Kirsh

Boston Scientific Genus Family Stimview XT 2 image-guided software DBS
[Image courtesy of Boston Scientific]
Boston Scientific (NYSE:BSX) today announced it received FDA approval for its Vercise Neural Navigator with StimView XT.

The Marlborough, Massachusetts–based company designed its latest image-guided programming software in collaboration with Brainlab AG. It enables clinicians in real-time to visualize lead placement and stimulation modeling of the brain anatomy of patients with Parkinson’s disease or essential tremor.

StimView XT, combined with the Vercise Genus deep brain stimulation (DBS) portfolio, is an integrated visualization software for DBS programming. It enables patient-specific 3D visualization of the anatomy for clinicians to better personalize therapy for individual patient needs.

“It’s exciting that clinicians will now have access to more sophisticated image-guided programming tools supporting personalized DBS therapy,” said Dr. Jill Ostrem, medical director at the University of California San Francisco’s Movement Disorders and Neuromodulation Center. “This advancement with StimView XT may also save time for the clinician as it could help avoid the trial and error in finding the precise location. Prolonged periods of time in adjusting stimulation settings can be stressful and tiring for patients.”

A recent study of the Boston Scientific visualization system showed that clinicians were able to adjust patient stimulation in an average of 20 minutes and lowered programming time by 56%.

“Every person’s experience living with Parkinson’s disease or essential tremor is unique, and their treatment should be as unique,” Maulik Nanavaty, senior VP of neuromodulation at Boston Scientific, said in a news release. “Our technologies enable clinicians to precisely see, shape, and steer DBS therapy to meet their patients’ individual needs. This latest advancement is a testament to how we’ll continue to deliver on meaningful innovations that support doctors.”

Filed Under: Diagnostics, Digital Health, Featured, Neurological, Neuromodulation/Neurostimulation, News Well Tagged With: Boston Scientific

More recent news

  • Zenflow nets $52M, Cook Medical deal for in-office enlarged prostate implant
  • Abbott to update CardioMEMS to allow patients to track pulmonary artery pressure
  • Wandercraft acquires exoskeleton rival Ekso Bionics
  • GE HealthCare to buy Sofie Biosciences in $945M radiopharmaceutical play
  • Carlsmed names chief product and AI officer as it claims CMS reimbursements

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy